Aprea Therapeutics Inc (APRE)

Jan 21, 2025

Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is expected to grow by 2034 | DelveInsight - The Globe and Mail

Jan 21, 2025

Jan 20, 2025

Aprea Therapeutics Discloses Unaudited Financials and Updates Corporate PresentationAprea Therapeutics, Inc. recently released an updated corporate presentation, alongside disclosing financial information as of December 31, 2024. The company shared - Defense World

Jan 20, 2025

Jan 17, 2025

H.C. Wainwright sets target on Aprea stock, Buy rating on clinical update - MSN

Jan 17, 2025

Jan 17, 2025

HC Wainwright Reiterates Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World

Jan 17, 2025

Jan 09, 2025

Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MSN

Jan 09, 2025

Jan 07, 2025

Chronic Lymphocytic Leukemia Therapeutics Market Size in the 7MM is projected to grow during the forecast period 2024-2034 and estimated DelveInsight - The Globe and Mail

Jan 07, 2025

Jan 02, 2025

Lexicon Appoints Scott Coiante as Chief Financial Officer - The Manila Times

Jan 02, 2025

Jan 02, 2025

Lexicon Pharmaceuticals Names Veteran Pharma Executive Scott Coiante as New CFO - StockTitan

Jan 02, 2025

Dec 30, 2024

Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Expands By 16.4% - Defense World

Dec 30, 2024

Dec 19, 2024

HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World

Dec 19, 2024

Dec 11, 2024

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward - The Manila Times

Dec 11, 2024

Dec 11, 2024

Aprea Therapeutics Advances Novel Cancer Drug Trial with Breakthrough Dosing Strategy - StockTitan

Dec 11, 2024

Nov 22, 2024

Aprea Therapeutics Reports Q3 Financials and Advances in Clinical Trials - MSN

Nov 22, 2024

Nov 21, 2024

HC Wainwright Has Bullish Outlook for APRE FY2024 Earnings - Defense World

Nov 21, 2024

Nov 20, 2024

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher - MSN

Nov 20, 2024

Nov 20, 2024

Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024

Nov 11, 2024

Aprea Therapeutics (NASDAQ: APRE) Announces Financial Results and Corporate Updates - Defense World

Nov 11, 2024

Nov 10, 2024

Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 10, 2024

Nov 10, 2024

Health Catalyst signs definitive agreement to acquire Intraprise Health - MSN

Nov 10, 2024

Nov 07, 2024

Aprea Therapeutics Inc (APRE) Quarterly 10-Q Report - Quartz

Nov 07, 2024

Nov 07, 2024

Aprea Therapeutics Inc (APRE) Q3 2024 Earnings: Revenue Hits $0. - GuruFocus.com

Nov 07, 2024

Nov 07, 2024

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024

Oct 31, 2024

Larimar Therapeutics Reports Third-Quarter 2024 Financial and Operational Progress - MyChesCo

Oct 31, 2024

Oct 29, 2024

Aprea Therapeutics Presents Promising Safety Data for WEE1 Inhibitor at International Symposium - MSN

Oct 29, 2024

Oct 28, 2024

DDR Defective Tumors Market Growth Surge: Key Players and Market - openPR

Oct 28, 2024

Oct 27, 2024

Can Aprea Therapeutics (APRE) Spring Back This Year? - RTTNews

Oct 27, 2024

Oct 26, 2024

Aprea Therapeutics (NASDAQ:APRE) Rating Reiterated by HC Wainwright - Defense World

Oct 26, 2024

Oct 26, 2024

Aprea therapeutics director sells shares worth $29,583 By Investing.com - Investing.com South Africa

Oct 26, 2024

Oct 25, 2024

Aprea therapeutics director sells shares worth $29,583 - Investing.com India

Oct 25, 2024

Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock - Investing.com

Oct 24, 2024

Oct 24, 2024

Aprea Therapeutics presents preliminary results on APR-1051 - Yahoo Finance

Oct 24, 2024

Oct 24, 2024

Aprea therapeutics CEO Gilad Oren buys $1,957 in stock By Investing.com - Investing.com UK

Oct 24, 2024

Oct 23, 2024

Insider Spends US$132k Buying More Shares In Aprea Therapeutics - Yahoo Finance

Oct 23, 2024

Oct 23, 2024

Aprea Therapeutics falls on data from APR-1051 study in cancer-associated gene alterations - Seeking Alpha

Oct 23, 2024

Oct 23, 2024

Aprea reports safe trial results for new cancer drug - Investing.com

Oct 23, 2024

Oct 23, 2024

Aprea reports safe trial results for new cancer drug By Investing.com - Investing.com UK

Oct 23, 2024

Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics - The Manila Times

Oct 23, 2024

Oct 23, 2024

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR - EIN News

Oct 23, 2024

Oct 20, 2024

Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock - Simply Wall St

Oct 20, 2024

Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock By Investing.com - Investing.com South Africa

Oct 17, 2024

Oct 17, 2024

Aprea therapeutics director Duey Marc acquires $131,700 in stock - Investing.com India

Oct 17, 2024